GlassScriptPhysician profile
John W Lyzanchuk
NPI 1730199860
$10,769.89
in general payments reported to CMS, 2019-2025
39 companies · $1,612 in 2025
The $1,612 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $648 · 2021: $1,431 · 2022: $2,119 · 2023: $1,843 · 2024: $2,056 · 2025: $1,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,409 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,409.29 |
| Education | $100.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,696.57 | 2019-2025 | Farxiga, Breztri |
| Pfizer INC. | $1,131.63 | 2019-2025 | |
| Abbvie INC. | $1,027.08 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $894.19 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $871.02 | 2021-2025 | |
| Glaxosmithkline, LLC. | $716.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $712.38 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $586.63 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $429.09 | 2019-2022 | |
| Amgen INC. | $274.49 | 2019-2025 | Otezla, Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $253.01 | 2019-2023 | |
| Astellas Pharma US INC | $242.81 | 2019-2024 | Veozah |
| Sumitomo Pharma America, INC. | $216.20 | 2023-2025 | Gemtesa |
| Mylan Specialty L.P. | $190.11 | 2019-2023 | Yupelri |
| Lilly USA, LLC | $154.51 | 2019-2025 | Mounjaro, Zepbound |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $140.52 | 2025 | Arikayce, Brinsupri |
| Novartis Pharmaceuticals Corporation | $139.13 | 2021-2024 | |
| Daiichi Sankyo INC. | $129.23 | 2021-2025 | Injectafer |
| Sunovion Pharmaceuticals INC. | $127.00 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $99.84 | 2019-2023 | Eliquis |
| Xeris Pharmaceuticals, INC. | $88.93 | 2024 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $87.56 | 2022-2025 | Zoryve, Livalo, Seglentis |
| Esperion Therapeutics, INC. | $81.25 | 2020-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.35 | 2019-2025 | Xifaxan |
| Harmony Biosciences LLC | $54.40 | 2021-2023 | Wakix |
| Exact Sciences Corporation | $51.26 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amarin Pharma, INC. | $46.57 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $39.59 | 2019 | |
| Viatris Specialty LLC | $34.29 | 2025 | Yupelri |
| Mdd US Operations, LLC | $32.58 | 2019 | |
| Biogen, INC. | $27.65 | 2024 | Leqembi |
| Teva Pharmaceuticals USA, INC. | $25.53 | 2019-2022 | |
| Sanofi Pasteur INC. | $19.24 | 2022 | |
| Dexcom, INC. | $18.69 | 2023 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $17.95 | 2023 | Thinprep 2000 Processor |
| Allergan, INC. | $14.09 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.48 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Phathom Pharmaceuticals, INC. | $6.46 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lyzanchuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.